Clavis Pharma, Clovis Oncology and Ventana Medical Systems have entered into a collaboration agreement to develop a companion diagnostic to CP-4126, Clavis’s lead cancer drug candidate.

The companion diagnostic will be developed to identify pancreatic cancer patients with low-level tumour expression of the human equilibrative nucleoside transporter 1 protein who may be benefited from the company’s novel drug candidate.

CP-4126 has been licensed to Clovis in the Americas and Europe while Clavis retains rights in other regions and an option to co-promote CP-4126 in Europe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData